

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Robert P. Hebbel et al.  
**Title:** TRANSGENIC CIRCULATING ENDOTHELIAL CELLS

**Docket No.:** 600.449US1  
**Filed:** May 24, 2001  
**Examiner:** Quang Nguyen

**Serial No.:** 09/865,022  
**Due Date:** April 11, 2002  
**Group Art Unit:** 1636

Commissioner for Patents  
 Washington, D.C. 20231



**RECEIVED**

APR 23 2002

TECH CENTER 1600/2900

**RECEIVED**

APR 23 2002

TECH CENTER 1600/2900

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Supplemental Preliminary Amendment And Response To Restriction Requirement (4 Pages)
- ☒ A check in the amount of \$228.00 to cover the fee for additional claims as calculated below.
- ☒ Clean Version of Pending Claims (6 pgs.).

If an additional fee is required due to changes to the claims, the fee has been calculated as follows:

CLAIMS AS AMENDED						
	(1) Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Present Extra	Rate	Fee
TOTAL CLAIMS	49	-	41	8	x 18 =	\$144.00
INDEPENDENT CLAIMS	5	-	4	1	x 84 =	\$84.00
[ ] MULTIPLE DEPENDENT CLAIMS PRESENTED						\$0.00
TOTAL						\$228.00

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
 P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By:   
 Atty: Janet E. Embretson  
 Reg. No. 39,665

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 17th day of April, 2002.

Name

Signature

**Customer Number 21186**

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
 (GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

S/N 09/865,022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert P. Hebbel et al.

Examiner: Quang Nguyen


Serial No.: 09/865,022

Group Art Unit: 1636

Filed: May 24, 2001

Docket: 600.449US1

Title: TRANSGENIC CIRCULATING ENDOTHELIAL CELLS



SUPPLEMENTAL PRELIMINARY AMENDMENT AND  
RESPONSE TO RESTRICTION REQUIREMENT

**RECEIVED**

Commissioner for Patents  
Washington, D.C. 20231

APR 23 2002

TECH CENTER 1600/2900

In response to the Restriction Requirement mailed March 11, 2002, please amend the above-identified application as follows:

In the Claims

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set. Specific amendments are detailed below.

Please add the following claims:

- AI
37. (New) A transgenic endothelial cell comprising a vector comprising an isolated DNA sequence encoding a preselected protein operably linked to a promoter functional in human endothelial cells, which transgenic endothelial cell is prepared by introducing the vector into an expanded population of endothelial cells prepared by culturing, in contact with a collagen I-coated surface, buffy coat cells obtained from peripheral mammalian blood in the presence of a cell culture medium containing an effective amount of vascular endothelial growth factor (VEGF), and which medium is free of bovine brain extract.
  38. (New) The transgenic endothelial cell of claim 37 wherein the DNA sequence encodes a Factor VIII protein.
  39. (New) The transgenic endothelial cell of claim 37 wherein the DNA sequence comprises SEQ ID NO:1 or SEQ ID NO:2.

04/22/2002 RMEBRAHT 00000012 09865022

01 FC:103  
02 FC:102

144.00 OP  
84.00 OP